Axsome Therapeutics, Inc (AXSM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AXSM SEC filings page.
Axsome Therapeutics, Inc (AXSM) reported $776.6M in revenue over the twelve months to Jun 30, 2026, up 56.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling quickly, but operating leverage is only partial: growth produces narrower, not eliminated, cash losses.
Revenue more than doubled by FY2025 while operating margin improved to-26.1% , showing that incremental sales are reaching operating profit more efficiently, though not enough to produce profit. Gross margin also moved from91.4% to92.6% , so the improvement reflects operating cost absorption alongside a slightly stronger gross margin, not merely more volume.
Cash conversion remains the central constraint: operating cash flow was
Working capital is absorbing more funding: receivables reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Axsome Therapeutics, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Axsome Therapeutics, Inc has an operating margin of -26.1%, meaning the company loses $26 on every $100 of revenue. This results in a profitability score of 15/100. This is up from -72.7% the prior year.
Axsome Therapeutics, Inc's revenue surged 65.5% year-over-year to $638.5M, reflecting rapid business expansion. This strong growth earns a score of 95/100.
Axsome Therapeutics, Inc has a moderate D/E ratio of 1.33. This balance of debt and equity financing earns a leverage score of 41/100.
Axsome Therapeutics, Inc's current ratio of 1.55 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Axsome Therapeutics, Inc's operations used $93.4M of cash, and capex of $480K added to the outflow, for a free cash flow shortfall of $93.9M. This results in a cash flow score of 7/100.
Axsome Therapeutics, Inc posts a -207.5% return on equity (ROE), meaning it loses $207 for every $100 of shareholders' equity. This results in a returns score of 18/100. This is up from -503.8% the prior year.
Axsome Therapeutics, Inc scores 6.64, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.8B) relative to total liabilities ($601.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Axsome Therapeutics, Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Axsome Therapeutics, Inc reported a net loss of $183.2M while operations used $93.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Axsome Therapeutics, Inc reported an operating loss of $166.8M against $15.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Axsome Therapeutics, Inc generated $218.4M in revenue in Q2 2026. This represents an increase of 45.5% from the same quarter a year earlier. Against the prior quarter it is up 14.2%.
Axsome Therapeutics, Inc's EBITDA was -$46.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.7% from the same quarter a year earlier. Against the prior quarter it is up 23.3%.
Axsome Therapeutics, Inc reported -$51.3M in net income in Q2 2026. This represents a decrease of 7.0% from the same quarter a year earlier. Against the prior quarter it is up 20.5%.
Axsome Therapeutics, Inc earned -$0.99 per diluted share (EPS) in Q2 2026. This represents a decrease of 2.1% from the same quarter a year earlier. Against the prior quarter it is up 21.4%.
Cash & Balance Sheet
Axsome Therapeutics, Inc recorded an outflow of $33.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 3.0% from the same quarter a year earlier. Against the prior quarter it is down 60.4%.
Axsome Therapeutics, Inc held $319.9M in cash against $118.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Axsome Therapeutics, Inc's gross margin was 93.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
Axsome Therapeutics, Inc's operating margin was -22.7% in Q2 2026, reflecting core business profitability. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.4 percentage points.
Axsome Therapeutics, Inc's net profit margin was -23.5% in Q2 2026, showing the share of revenue converted to profit. This is up 8.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.3 percentage points.
Axsome Therapeutics, Inc's ROE was -61.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 56.6 percentage points.
Capital Allocation
Axsome Therapeutics, Inc invested $46.2M in research and development in Q2 2026. This represents a decrease of 6.7% from the same quarter a year earlier. Against the prior quarter it is down 12.2%.
Axsome Therapeutics, Inc invested $450K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 3361.5% from the same quarter a year earlier. Against the prior quarter it is up 271.9%.
Not reported for Q2 2026.
AXSM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $218.4M+45.5% | $191.2M+57.4% | $196.0M+65.0% | $171.0M+63.2% | $150.0M+72.1% | $121.5M+62.0% | $118.8M+66.0% | $104.8M+81.3% |
| Cost of Revenue | $13.6M+0.9% | $14.7M+50.4% | $12.3M+17.3% | $11.9M+41.2% | $13.4M+67.0% | $9.8M+55.5% | $10.5M+42.5% | $8.4M+29.2% |
| Gross Profit | $204.8M+49.9% | $176.5M+58.0% | $183.7M+69.7% | $159.1M+65.1% | $136.6M+72.7% | $111.7M+62.5% | $108.3M+68.7% | $96.3M+87.9% |
| R&D Expenses | $46.2M-6.7% | $52.7M+17.6% | $48.8M-11.3% | $40.2M-11.5% | $49.5M-0.6% | $44.8M+21.6% | $55.0M+78.6% | $45.4M+57.8% |
| SG&A Expenses | $208.1M+59.8% | $185.0M+53.2% | $169.3M+49.5% | $150.2M+57.2% | $130.3M+25.8% | $120.8M+22.0% | $113.3M+30.5% | $95.6M+14.9% |
| Operating Income | -$49.6M-35.2% | -$63.4M-11.2% | -$27.0M+62.9% | -$46.1M+26.4% | -$36.7M+53.0% | -$57.0M+15.3% | -$72.6M+26.1% | -$62.6M-0.8% |
| EBITDA | -$46.8M-35.7% | -$61.0M-11.2% | -$24.7M+65.0% | -$43.7M+27.8% | -$34.5M+54.7% | -$54.8M+16.2% | -$70.5M+26.9% | -$60.6M-0.3% |
| Interest Expense | -$3.2M+21.7% | $3.1M-41.2% | -$13.7M-152.8% | -$3.4M+40.4% | -$4.1M+19.6% | $5.3M+197.3% | -$5.4M+83.4% | -$5.7M-215.9% |
| Income Tax | $128K+113.3% | $0 | $430K+405.9% | $0 | -$960K | $0 | $85K+126.2% | $0+100.0% |
| Net Income | -$51.3M-7.0% | -$64.5M-8.6% | -$28.6M+61.9% | -$47.2M+26.9% | -$48.0M+39.5% | -$59.4M+13.1% | -$74.9M+24.1% | -$64.6M-3.9% |
| EPS (Basic) | -$0.99-2.1% | -$1.26-3.3% | -$0.55+64.3% | -$0.94+29.9% | -$0.97+41.9% | -$1.22+15.3% | -$1.54+27.7% | -$1.34-1.5% |
| EPS (Diluted) | -$0.99-2.1% | -$1.26-3.3% | -$0.55+64.3% | -$0.94+29.9% | -$0.97+41.9% | -$1.22+15.3% | -$1.54+27.7% | -$1.34-1.5% |
| Diluted Shares (Avg) | 52M+4.8% | 51M+4.8% | N/A | 50M+3.9% | 49M+3.9% | 49M+3.1% | N/A | 48M+2.2% |
AXSM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $761.4M+19.0% | $713.6M+19.6% | $689.8M+21.3% | $669.3M+19.2% | $639.8M+16.7% | $596.7M+9.3% | $568.5M-3.4% | $561.5M-6.6% |
| Current Assets | $656.6M+22.4% | $611.2M+23.6% | $589.0M+21.4% | $565.3M+18.0% | $536.6M+15.9% | $494.6M+7.4% | $485.1M-3.8% | $479.1M-6.4% |
| Cash & Equivalents | $319.9M+5.6% | $305.1M+1.4% | $322.9M+2.4% | $325.3M-0.6% | $303.0M-4.0% | $300.9M-9.2% | $315.4M-18.3% | $327.3M-21.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $37.9M+105.4% | $31.5M+93.1% | $27.9M+77.6% | $23.8M+66.7% | $18.4M+21.2% | $16.3M+4.7% | $15.7M+3.9% | $14.3M+42.9% |
| Accounts Receivable | $277.5M+39.5% | $251.1M+55.6% | $224.5M+58.1% | $196.5M+58.4% | $198.8M+65.2% | $161.4M+59.1% | $142.0M+49.8% | $124.1M+58.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% | $12.0M0.0% |
| Total Liabilities | $678.1M+19.7% | $659.0M+21.3% | $601.5M+17.6% | $595.5M+27.1% | $566.7M+27.2% | $543.5M+35.3% | $511.5M+28.8% | $468.6M+41.4% |
| Current Liabilities | $460.4M+34.6% | $439.2M+80.1% | $378.8M+64.6% | $360.3M+83.6% | $342.1M+83.4% | $243.9M+69.3% | $230.1M+65.7% | $196.2M+71.1% |
| Non-Current Liabilities | $217.7M-3.1% | $219.8M-26.6% | $222.7M-20.9% | $235.2M-13.6% | $224.6M-13.2% | $299.6M+16.3% | $281.4M+8.9% | $272.4M+25.7% |
| Long-Term Debt | $118.0M+0.4% | $117.8M-35.0% | $117.7M-34.8% | $117.6M-34.6% | $117.5M-34.5% | $181.4M+1.5% | $180.7M+1.5% | $180.0M+1.4% |
| Total Equity | $83.3M+14.0% | $54.6M+2.6% | $88.3M+54.9% | $73.7M-20.6% | $73.1M-29.0% | $53.2M-63.1% | $57.0M-70.1% | $92.9M-65.5% |
| Retained Earnings | -$1.4B-15.6% | -$1.4B-15.9% | -$1.3B-16.3% | -$1.3B-21.9% | -$1.2B-25.1% | -$1.2B-30.8% | -$1.1B-34.4% | -$1.0B-42.2% |
AXSM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.0M-1.6% | -$20.7M+52.3% | -$18.7M+28.8% | $1.0M+105.6% | -$32.4M-7.7% | -$43.4M+18.9% | -$26.2M+13.7% | -$18.6M+65.2% |
| Depreciation & Amortization | $2.9M+28.5% | $2.4M+11.0% | $2.3M+9.7% | $2.4M+17.0% | $2.2M+12.7% | $2.1M+16.5% | $2.1M+19.1% | $2.1M+18.2% |
| Stock-Based Compensation | $27.1M+10.3% | $23.4M+0.6% | N/A | $23.1M+6.7% | $24.6M+15.1% | $23.3M+15.4% | N/A | $21.7M+32.3% |
| Capital Expenditures | $450K+3361.5% | $121K-64.2% | $71K+136.7% | $58K-35.6% | $13K-75.0% | $338K+244.9% | $30K+328.6% | $90K-75.7% |
| Free Cash Flow | -$33.4M-3.0% | -$20.8M+52.4% | -$18.7M+28.6% | $988K+105.3% | -$32.4M-7.5% | -$43.7M+18.4% | -$26.2M+13.6% | -$18.7M+65.3% |
| Investing Cash Flow | -$450K-3361.5% | -$121K+64.2% | -$71K-136.7% | -$58K+35.6% | -$13K+75.0% | -$338K-244.9% | -$30K-328.6% | -$90K+75.7% |
| Financing Cash Flow | $48.1M+39.4% | $3.0M-89.8% | $16.4M+15.0% | $21.3M-30.1% | $34.5M+140.2% | $29.3M+2565.9% | $14.2M+712300.0% | $30.4M-8.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AXSM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.8%+2.7pp | 92.3%+0.4pp | 93.7%+2.6pp | 93.0%+1.1pp | 91.0%+0.3pp | 91.9%+0.3pp | 91.1%+1.5pp | 92.0%+3.2pp |
| Operating Margin | -22.7%+1.7pp | -33.1%+13.8pp | -13.8%+47.4pp | -27.0%+32.8pp | -24.5%+65.1pp | -46.9%+42.8pp | -61.1% | -59.8% |
| Net Margin | -23.5%+8.5pp | -33.8%+15.1pp | -14.6%+48.5pp | -27.6%+34.1pp | -32.0%+59.1pp | -48.9%+42.2pp | -63.1% | -61.7% |
| Return on Equity | -61.6%+4.0pp | -118.2%-6.6pp | -32.3%+99.0pp | -64.1%+5.5pp | -65.6%+11.5pp | -111.7%-64.2pp | -131.4%-79.7pp | -69.5%-46.5pp |
| Return on Assets | -6.7%+0.8pp | -9.0%+0.9pp | -4.1%+9.0pp | -7.1%+4.5pp | -7.5%+7.0pp | -10.0%+2.6pp | -13.2%+3.6pp | -11.5%-1.2pp |
| Current Ratio | 1.43-0.1x | 1.39-0.6x | 1.55-0.6x | 1.57-0.9x | 1.57-0.9x | 2.03-1.2x | 2.11-1.5x | 2.44-2.0x |
| Debt-to-Equity | 1.42-0.2x | 2.16-1.3x | 1.33-1.8x | 1.60-0.3x | 1.61-0.1x | 3.41+2.2x | 3.17+2.2x | 1.94+1.3x |
| Asset Turnover | 0.29+0.1x | 0.27+0.1x | 0.28+0.1x | 0.26+0.1x | 0.23+0.1x | 0.20+0.1x | 0.21+0.1x | 0.19+0.1x |
| FCF Margin | -15.3%+6.3pp | -10.9%+25.1pp | -9.6%+12.5pp | 0.6%+18.4pp | -21.6%+13.0pp | -36.0%+35.4pp | -22.1%+20.4pp | -17.9%+75.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc AXSM | FY2025 | $638.5M | -$183.2M | -28.7% | $8.8B | 37/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $3.6B | 41/100 |
| Cytokinetics Inc. CYTK | FY2025 | $88.0M | -$785.0M | N/A | $8.7B | 60/100 |
| Rhythm Pharmaceuticals, Inc. RYTM | FY2025 | $189.8M | -$197K | -0.1% | $6.3B | 65/100 |
| Nuvalent, Inc. NUVL | FY2025 | N/A | -$425.4M | N/A | $9.8B | — |
Where Axsome Therapeutics, Inc Ranks
Frequently Asked Questions
What is Axsome Therapeutics, Inc's annual revenue?
Axsome Therapeutics, Inc (AXSM) reported $638.5M in total revenue for fiscal year 2025. This represents a 65.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Axsome Therapeutics, Inc's revenue growing?
Axsome Therapeutics, Inc (AXSM) revenue grew by 65.5% year-over-year, from $385.7M to $638.5M in fiscal year 2025.
Is Axsome Therapeutics, Inc profitable?
No, Axsome Therapeutics, Inc (AXSM) reported a net income of -$183.2M in fiscal year 2025, with a net profit margin of -28.7%.
What is Axsome Therapeutics, Inc's EBITDA?
Axsome Therapeutics, Inc (AXSM) had EBITDA of -$157.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Axsome Therapeutics, Inc have?
As of fiscal year 2025, Axsome Therapeutics, Inc (AXSM) had $322.9M in cash and equivalents against $117.7M in long-term debt.
What is Axsome Therapeutics, Inc's gross margin?
Axsome Therapeutics, Inc (AXSM) had a gross margin of 92.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Axsome Therapeutics, Inc's operating margin?
Axsome Therapeutics, Inc (AXSM) had an operating margin of -26.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Axsome Therapeutics, Inc's net profit margin?
Axsome Therapeutics, Inc (AXSM) had a net profit margin of -28.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Axsome Therapeutics, Inc's return on equity (ROE)?
Axsome Therapeutics, Inc (AXSM) has a return on equity of -207.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Axsome Therapeutics, Inc's free cash flow?
Axsome Therapeutics, Inc (AXSM) recorded an outflow of $93.9M in free cash flow during fiscal year 2025. This represents a 27.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Axsome Therapeutics, Inc's operating cash flow?
Axsome Therapeutics, Inc (AXSM) recorded an outflow of $93.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Axsome Therapeutics, Inc's total assets?
Axsome Therapeutics, Inc (AXSM) had $689.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Axsome Therapeutics, Inc's capital expenditures?
Axsome Therapeutics, Inc (AXSM) invested $480K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Axsome Therapeutics, Inc spend on research and development?
Axsome Therapeutics, Inc (AXSM) invested $183.3M in research and development during fiscal year 2025.
What is Axsome Therapeutics, Inc's current ratio?
Axsome Therapeutics, Inc (AXSM) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.
What is Axsome Therapeutics, Inc's debt-to-equity ratio?
Axsome Therapeutics, Inc (AXSM) had a debt-to-equity ratio of 1.33 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Axsome Therapeutics, Inc's return on assets (ROA)?
Axsome Therapeutics, Inc (AXSM) had a return on assets of -26.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Axsome Therapeutics, Inc's P/E ratio?
Axsome Therapeutics, Inc (AXSM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $8.8B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Axsome Therapeutics, Inc's price-to-sales ratio?
Axsome Therapeutics, Inc (AXSM) trades at 11.4x sales, its market capitalization divided by revenue of $776.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $8.8B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Axsome Therapeutics, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Axsome Therapeutics, Inc (AXSM) held $322.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $93.4M over that year. Dividing the one by the other, the reported balance equals about 41 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Axsome Therapeutics, Inc's Altman Z-Score?
Axsome Therapeutics, Inc (AXSM) has an Altman Z-Score of 6.64, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Axsome Therapeutics, Inc's Piotroski F-Score?
Axsome Therapeutics, Inc (AXSM) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Axsome Therapeutics, Inc's earnings high quality?
Axsome Therapeutics, Inc (AXSM) reported a net loss of $183.2M while operations used $93.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Axsome Therapeutics, Inc cover its interest payments?
Axsome Therapeutics, Inc (AXSM) reported an operating loss of $166.8M against $15.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Axsome Therapeutics, Inc?
Axsome Therapeutics, Inc (AXSM) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.